Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KYJRR
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Alpha-CD22-LC-K149C-12
|
|||||
| Synonyms |
AlphaCD22-LC-K149C-12
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Anti-CD22-LC-K149C
|
Antibody Info | ||||
| Antigen Name |
B-cell receptor CD22 (CD22)
|
Antigen Info | ||||
| Payload Name |
Seco-CBI-dimer 12
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-peptidomimetic based linker 12
|
Linker Info | ||||
The indication landscape of This ADC(2027 Update)
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.23 nM | Positive CD22 expression (CD22+++/++) | ||
| Method Description |
Seco-CBI-Dimer TDCs Exhibit Potent Antigen-Dependent Antiproliferation Effects in Vitro. All cell-based assay results are reported as the arithmetic mean of at least three separate runs (n = 3).
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | WSU-DLCL2 cells | CVCL_1902 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 9.8 nM | Positive CD22 expression (CD22+++/++) | ||
| Method Description |
Seco-CBI-Dimer TDCs Exhibit Potent Antigen-Dependent Antiproliferation Effects in Vitro. All cell-based assay results are reported as the arithmetic mean of at least three separate runs (n = 3).
|
||||
| In Vitro Model | Burkitt lymphoma | BJAB cells | CVCL_5711 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 133 nM | Positive CD22 expression (CD22+++/++) | ||
| Method Description |
Seco-CBI-Dimer TDCs Exhibit Potent Antigen-Dependent Antiproliferation Effects in Vitro. All cell-based assay results are reported as the arithmetic mean of at least three separate runs (n = 3).
|
||||
| In Vitro Model | T acute lymphoblastic leukemia | Jurkat cells | CVCL_0065 | ||
References